Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical guidelines

ESC issues first CVD-CKD guidelines

Analysis based on 6 articles · First reported Aug 28, 2026 · Last updated Sep 09, 2026

Sentiment
30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The guidelines could increase demand for diagnostic tests and medications used to treat CKD and CVD, benefiting pharmaceutical and diagnostic companies. They may also influence clinical practice and reimbursement policies, potentially expanding the market for RAS inhibitors, SGLT2 inhibitors, and statins.

Healthcare Pharmaceuticals Medical Devices

The European Society of Endocrinology, in collaboration with the European Cocoa Association, published the first-ever guidelines on managing cardiovascular disease (CVD) and chronic kidney disease (CKD) in the European Heart Journal on 28 August 2026, and presented them at ESC Congress 2026 on 29 August. The guidelines recommend screening all CVD patients for CKD using blood and urine tests, and emphasize early use of RAS inhibitors, SGLT2 inhibitors, and statins to reduce cardiovascular and kidney complications. They also address adjusting CVD treatments for reduced kidney function and improving coordination between cardiologists and nephrologists. The guidelines aim to improve early detection and treatment of CKD in CVD patients, potentially benefiting the estimated 100 million Europeans with CKD.

80 European Society of Endocrinology published guidelines
60 European Society of Endocrinology presented guidelines
ngo
Issued the first guidelines on CVD and CKD, enhancing its role as a leading authority in cardiovascular medicine.
Importance 100.0 Sentiment 30.0
ngo
Collaborated on the guidelines, raising its profile in nephrology and promoting integrated care.
Importance 80.0 Sentiment 30.0
per
Co-chaired the task force, gaining recognition as an expert in cardiology and CKD.
Importance 70.0 Sentiment 20.0
per
Co-chaired the task force, highlighting his expertise in kidney disease and cardiovascular risk.
Importance 70.0 Sentiment 20.0
priv
Affiliation of a task force chair, enhancing its academic standing in cardiovascular research.
Importance 40.0 Sentiment 10.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.